



SAFETY DATA SHEET

Revision date 30-May-2022

Version 1.01

Page 1 / 11

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Product Code(s) PZ03165
Trade Name: Not applicable
Chemical Family: Opioid analgesic

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as opioid analgesic

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

Reproductive toxicity Category 1B Effects on or via lactation

2.2. Label elements

Signal word Danger

Hazard statements H360 - May damage fertility or the unborn child
H362 - May cause harm to breast-fed children

Precautionary Statements P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P260 - Do not breathe dust/fume/gas/mist/vapors/spray
P264 - Wash hands thoroughly after handling
P270 - Do not eat, drink or smoke when using this product
P263 - Avoid contact during pregnancy/while nursing
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 30-May-2022

Page 2 / 11
Version 1.01



2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
SODIUM CHLORIDE (CAS #: 7647-14-5)	<1	-	231-598-3	Not classified as hazardous	Not Listed	No data available	No data available
Butorphanol tartrate (CAS #: 58786-99-5)	< 0.2		261-443-5	Acute Tox. 4 (H302) Repr. 1B (H360D) Lact. (H362)	Not Listed	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified as hazardous	Not Listed	No data available	No data available
Sodium citrate (CAS #: 68-04-2)	*	-	200-675-3	Not classified as hazardous	Not Listed	No data available	No data available
Citric acid monohydrate (CAS #: 5949-29-1)	*	-	Not Listed	Skin Irrit. 2 (H315) Eye Irrit. 2 (H319) STOT SE 3 (H335)	Not Listed	No data available	No data available

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 30-May-2022

Page 3 / 11
Version 1.01

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate
No information available

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
SODIUM CHLORIDE 7647-14-5	3000	10000	No data available	No data available	No data available
Butorphanol tartrate 58786-99-5	570	No data available	No data available	No data available	No data available

Additional information

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for completeness.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Fine particles (such as mists) may fuel fires/explosions.

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 30-May-2022

Page 4 / 11
Version 1.01

Hazardous combustion products Formation of toxic gases is possible during heating or fire.

5.3. Advice for firefighters

Special protective equipment for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical product used as. opioid analgesic.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Butorphanol tartrate

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 30-May-2022

Page 5 / 11
Version 1.01

Pfizer OEL TWA-8 Hr: 3 µg/m³

SODIUM CHLORIDE

Latvia
Russia

5 mg/m³
MAC: 5 mg/m³

Pfizer Occupational Exposure Band (OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. Keep air contamination levels below the exposure limits or within the OEB range listed above in this section. General room ventilation is adequate unless the process generates dust, mist or fumes.

Environmental exposure controls

No information available.

Personal protective equipment

Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection

Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection

Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.).

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state

Solution

Color

Clear, colorless

Odor

No information available.

Odor threshold

No information available

Molecular formula

Mixture

Molecular weight

Mixture

Property

Values

pH

No data available

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 30-May-2022

Page 6 / 11
Version 1.01

Melting point / freezing point	No data available
Boiling point / boiling range	
Flash point	No information available
Evaporation rate	No data available
Flammability (solid, gas)	No data available
Flammability Limit in Air	
Upper flammability limit:	No data available
Lower flammability limit:	No data available
Vapor pressure	No data available
Vapor density	No data available
Relative density	No data available
Water solubility	No data available
Solubility(ies)	No data available
Partition coefficient	No data available
Autoignition temperature	No data available
Decomposition temperature	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available
Explosive properties	No information available

9.2. Other information

No information available

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No data available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to Mechanical Impact No data available.

Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 30-May-2022

Page 7 / 11
Version 1.01

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information:	Toxicological properties of the formulation have not been investigated. The information in this section describes the potential hazards of the individual ingredients and the formulation. Routes of exposure: eye contact , skin contact
Short term	May be harmful if swallowed. May cause eye irritation. May cause slight skin irritation.
Long Term:	Animal studies have shown a potential to cause adverse effects on the fetus. Repeat-dose studies in animals have shown a potential to cause adverse effects on reproductive system
Known Clinical Effects:	Ingestion of this material may cause effects similar to those seen in clinical use including dry mouth, drowsiness, headache, dizziness, nausea, vomiting, weakness, anxiety, blurred vision and dilated pupils. Cases of overdosage may also lead to respiratory depression, hypotension, coma, convulsions, cardiac arrhythmia, and tachycardia.
Acute toxicity	Based on available data, the classification criteria are not met.
Serious eye damage/eye irritation	Based on available data, the classification criteria are not met.
Skin corrosion/irritation	Based on available data, the classification criteria are not met.
Respiratory or skin sensitization	Based on available data, the classification criteria are not met.
STOT - single exposure	Based on available data, the classification criteria are not met.
STOT - repeated exposure	Based on available data, the classification criteria are not met.
Reproductive toxicity	Based on available data, the classification criteria are not met.
Germ cell mutagenicity	Based on available data, the classification criteria are not met.
Carcinogenicity	Based on available data, the classification criteria are not met.
Aspiration hazard	Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³

Rat Oral LD 50 3 g/kg

Mouse Oral LD 50 4 g/kg

Rabbit Dermal LD 50 > 10 g/kg

Butorphanol tartrate

Rat Oral LD50 570 mg/kg

Mouse Oral LD 50 395 mg/kg

Rat Intravenous LD 50 17 mg/kg

Mouse Intravenous LD 50 40.1 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
SODIUM CHLORIDE	= 3 g/kg (Rat)	> 10000 mg/kg (Rabbit)	> 42 mg/L (Rat) 1 h
Butorphanol tartrate	= 570 mg/kg (Rat)	-	-

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin irritation Rabbit Mild

Eye irritation Rabbit Mild

Citric acid monohydrate

Eye Irritation Rabbit Moderate

Skin Irritation Rabbit Moderate

Irritation / Sensitization Comments:

Eye Irritation / Sensitization May cause eye irritation

Skin Irritation / Sensitization May cause mild skin irritation.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Butorphanol tartrate

4 Week(s) Monkey Oral 10 mg/kg/day NOAEL None identified

3 Month(s) Rat Subcutaneous 5 mg/kg/day NOAEL None identified

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 30-May-2022

Page 8 / 11
Version 1.01

6 Month(s) Monkey Intramuscular 0.15 mg/kg/day LOEL None identified
6 Month(s) Rat Intramuscular 0.4 mg/kg/day LOEL None identified

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Butorphanol tartrate

Reproductive & Fertility Rat Oral 2.5 mg/kg/day NOAEL Fertility
Embryo / Fetal Development Rat Oral Dose not specified NOAEL Not Teratogenic
Reproductive & Fertility Rat Subcutaneous 1 mg/kg/day LOAEL Fetal mortality
Fertility and Embryonic Development Rabbit Oral 30 mg/kg/day NOAEL Fertility
Fertility and Embryonic Development Rabbit Oral 60 mg/kg/day NOAEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Butorphanol tartrate

Bacterial Mutagenicity (Ames) *Salmonella* , *E. coli* Negative
Unscheduled DNA Synthesis Human fibroblast cells Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Butorphanol tartrate

2 Year(s) Rat Oral 60 mg/kg/day NOAEL Not carcinogenic
2 Year(s) Mouse Oral 60 mg/kg/day NOAEL Not carcinogenic

Carcinogenicity None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties No information available.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties of the formulation have not been investigated. Releases to the environment should be avoided.

12.1. Toxicity

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment No information available.

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 30-May-2022

Page 9 / 11
Version 1.01

Chemical name	PBT and vPvB assessment
Sodium citrate	The substance is not PBT / vPvB PBT assessment does not apply
SODIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does not apply
Citric acid monohydrate	The substance is not PBT / vPvB

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number: Not applicable
UN proper shipping name: Not applicable
Transport hazard class(es): Not applicable
Packing group: Not applicable
Environmental Hazard(s): Not applicable

Special precautions for user: Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present

Sodium citrate

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 30-May-2022

Page 10 / 11
Version 1.01

EINECS	200-675-3
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5
SODIUM CHLORIDE	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-598-3
AICS	Present
Citric acid monohydrate	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
AICS	Present
Butorphanol tartrate	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	261-443-5

Chemical name	French RG number	Title
SODIUM CHLORIDE 7647-14-5	RG 78	-

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

Chemical name	Plant protection products directive (91/414/EEC)
SODIUM CHLORIDE - 7647-14-5	Plant protection agent

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

SAFETY DATA SHEET

Product Name Butorphanol Tartrate Injection (Hospira Inc)
Revision date 30-May-2022

Page 11 / 11
Version 1.01

Full text of H-Statements referred to under section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
Reproductive toxicity, effects on or via lactation; H362 - May cause harm to breast-fed children

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reason for revision Updated Section 3 - Composition / Information on Ingredients. Updated Section 5 - Fire Fighting Measures. Updated Section 6 - Accidental Release Measures. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information.

Revision date 30-May-2022

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.